Presentation is loading. Please wait.

Presentation is loading. Please wait.

Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :1729-1738.

Published byDoris Potter Modified over 8 years ago

Similar presentations

Presentation on theme: "Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :1729-1738."— Presentation transcript:

1 Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :1729-1738

2 Objectives ● To present final analysis of fracture endpoints, thru July 7, 2002. ● To test the hypothesis that the effect of E+P on fracture differed by risk factors for fracture. ● To report BMD results. ● To test whether the risk-benefit profile of E+P differs in women at higher vs. lower risk of hip fracture.

3 Outcomes ● All Fractures except ribs, chest/sternum, skull/face, fingers, toes and cervical vertebrae; ►Radiographically confirmed; ►Hip Fractures centrally adjudicated ● BMD : baseline, years 1 and 3 ● Global Index

4 Statistical Analyses ● Intent to Treat ● Cox Proportional Hazard Models (95% CI) ● Hip Fractures: Adjusted CI – 1 of 8 clinical outcomes monitored by DSMB All other Fractures: Nominal CI

5 Summary FRACTURE Risk Score Age1.14 0-7* Prior Fracture > age 552.22 2 Current Smoker2.31 2 Low BMI 1.91 1 Risk FactorOR Points * Age 50-53 = 0; age 54-57 = 1; age 58-61=2; age 62-64=3; age 65-68=4; age 69-72=5; age 73-75=6; age 76-79=7 Black D et al, Osteoporosis Int 2001;12:519-529 ROC Curve AUC = 0.79 (95% CI 0.73-0.84)

6 Baseline Characteristics across Categories of Summary FRACTURE Risk Score “Low”“Moderate”“High” (n)(4743)(5871)(3146) Age (y)566572 BMI (kg/m 2 )302927 Caucasian (%)778590 Past HT (%)191922 Current HT (%)1053 Current Smoke (%)31316 Fracture History (%)242859 Osteoporotic (%) a 12 23 41 a = T-score <-2.5, n=1024

7 Prevalence of Osteoporosis by DXA: Femoral Neck T-scores (WHO) (n=1024) NormalLow Bone MassOsteoporosis P = 0.29 Estrogen Plus ProgestinPlacebo

8 Hip Fracture 0.110.16 35% HR = 0.65 Total Fracture 24% 1.52 1.99 nCI=0.47 tp 0.96 aCI= 0.41 to 1.10 Annualized Incidence of Fractures (%) HR = 0.76 nCI=0.69 to 0.83 24% Reduction 35% Reduction n= nominal 95% CI a= adjusted 95% CI Annualized Incidence of Fractures (%) Effects of Estrogen plus Progestin on Hip and Total Fractures 52 hip fx 73 hip fx 733 fx 986 fx

9 Effects of Estrogen plus Progestin on Wrist and Vertebral Fractures Wrist/Lower Arm 0.43 0.59 28% HR = 0.72 nC I= 0.60 to 0.87 n=nominal 95% CI HR = 0.66 nCI = 0.44 to 0.98 Clinical Vertebral 31% 0.09 0.15 28% Reduction 31% Reduction 189 fx 245 fx 41 fx60 fx

10 Age (y) 50-54 55-59 60-64 65-69 70-74 75-79 1.0 10.1 0.76* Favors E&P Favors Placebo P(interaction) = 0.47 * Overall HR Hazard Ratio (95% CI) Effects of Estrogen Plus Progestin on Total Fractures by Age

11 The Effect of Estrogen + Progestin on Fractures was similar in different subgroups ● Years Since menopause ● Race/ethnicity ● BMI ● Smoking ● Falls ● Calcium Intake ● Parental History of Fracture ● Personal History Of Fracture ● Past use of HT ● BMD ● Summary Fracture risk score All Interactions were Not Statistically Significant

12 Effects of Estrogen plus Progestin on Total Fractures by Summary FRACTURE Risk Score Fracture Summary Score 0.85 (0.70, 1.03) 0.68 (0.28, 0.81) 0.82 (0.66, 1.02) p (interaction) = 0.54 1.10 1.33 1.41 1.99 2.33 2.74 Placebo E+P Annualized Incidence of Fracture (Percent (341 fx) (434 fx) (672 fx)

13 Greenspan 1998 Komulainen 1997 Wilalawansa 1998 Hulley 1998 Hosking 1998 Alexandersen 1999 Pooled Estimate (HR=0.87) Cauley (WHI) (HR=0.75) 1 100.01.1 10 Favors E&P Favors Placebo * Wells G et al Endocrine Reviews 2002;23:529-539 Comparison of WHI E + P results on Non-Spine Fractures with ORAG* report

14 Mean change from baseline in bone mineral density (BMD) at the Lumbar Spine during 3 years of follow-up - 1 0 1 2 3 4 5 6 7 0123 Follow-up, years Change in Spine BMD from Baseline Value, % E+P Placebo 4.5% Difference

15 Effects of Estrogen plus Progestin on the Global Index by FRACTURE Risk Score Tertiles Summary Score p (interaction) = 0.54 Placebo E+P HR=1.20 (0.93, 1.55) 0.96 0.81 1.55 1.89 HR=1.23 (1.04, 1.46) 2.94 2.84 HR=1.03 (0.86 – 1.24) Annualized (%) Incidence of Global Index Event

16 Limitations ● One estrogen plus progestin regimen ● Fracture risk score: ratio of highest to lowest risk was modest 2.0  No BMD measurements  No prevalent Vertebral fracture  May have better benefit/risk profile in women at higher risk. ● Clinical Vertebral Fractures ● Global Index: Potentially life threatening illness  Vertebral fractures

17 Summary ● Estrogen plus Progestin increases BMD and reduces the risk of fracture in healthy pre-dominantly non- osteoporotic women. ● Decreased risk of fracture was present in all subgroups of women examined ● The Effect of E+P on fracture is consistent with recent Meta-analyses. ● The effect of E+P on the Global Index did not differ across tertiles of fracture risk. There was no evidence of a net benefit in women at high risk of fracture.

18 Conclusion  Given: Overall unfavorable risk- benefit ratio Availability of other agents for the prevention and treatment of osteoporosis  Estrogen plus progestin cannot be recommended for the prevention or the treatment of osteoporosis in asymptomatic women.  Before the combination of estrogen and progestin is considered for the purpose of fracture prevention, women should be fully informed about the potential adverse effects.

19 Extra Slides

20 Comparison of Osteoporosis Therapies: ORAG InterventionNo. of trials/patients RR(95% CI) p Calcium2(222)0.86 (0.43,1.72)0.54 Vit D6(6187)0.77 (0.57,1.04)0.09 Alen.(5mg)8(8603)0.87 (0.73,1.02)0.09 Alen. (10-40)6(3723)0.51 (0.38,0.69)<0.01 Raloxifene7(6961)0.91 (0.79,1.06)0.24 Calcitonin1(1245)0.80 (0.59,1.09)0.16 Risedr.7(12958)0.73 (0.61,0.87)<0.01 HT-pre WHI6(3986)0.87 (0.71,1.08)0.10 HT WHI1(16608)0.75 (0.68,0.83)<0.05 Cranney A et al Endocrine Reviews 2002; 23(4): 570

21 NNT for 2 years to prevent a non-vertebral fracture: Low and High risk group Vitamin D 1 ?? Alendronate 1 ?24 Risedronate 1 ?43 Raloxifene 1 ?? E+P(WHI)106? WHI: women considered “low” risk WHI: women considered “low” risk Low risk High Risk WHI : women considered “low” risk 1. Cranney et al, 2002

22 NNT for 2 years to prevent a vertebral fracture: Low and High risk group Vitamin D 1 225294 Alendronate 1 179072 Risedronate 1 225294 Raloxifene 1 238199 E+P(WHI) 833--- Low risk High Risk WHI: Clinical Vertebral Fractures ; women considered “low” risk. 1. Cranney et al, 2002

23 Lumbar spine ORAG a 1 year 2 year WHI1 year 3 year Femoral Neck ORAG1 year 2 year WHI1 year 3 year 0 10 Favors E & P Favors Placebo a Wells G et al Endocrine Reviews 2002;23(4):529-539 Weighted Mean Difference (95% CI) 5 -5 Mean Difference in Percent Change in Bone Density after Treatment with E + P : ORAG a vs WHI

24 Bone Mineral Density by Randomized Group Total Hip5460.834780.840.77 Lumbar Spine5280.944610.950.87 T-score Total Hip546-0.94478-0.910.79 Lumbar Spine528-1.30461-1.260.87 BMD (g/cm 2 ) (n) E+P (n) Placebo p

25 Distribution of Summary Fracture Risk Score By Randomized Group Summary Risk Score E&P Placebo (points) n (%) n(%) Low (0-2)2393 (34.5) 2350 (34.4) Moderate (3-5)2691 (42.7) 2910 (42.6) High (>5)1575 (22.7) 1571 (23.0) P=0.93

Download ppt "Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :1729-1738."

Similar presentations

Preventing Bone Loss in Early Postmenopausal Women A CME Slide Library From the Council on Hormone Education.

Preventing Bone Loss in Early Postmenopausal Women A CME Slide Library From the Council on Hormone Education.
New Data on Ultra Low-Dose Estradiol Therapy in Osteoporosis Prevention New Data on Ultra Low-Dose Estradiol Therapy in Osteoporosis Prevention Marie Foegh,

New Data on Ultra Low-Dose Estradiol Therapy in Osteoporosis Prevention New Data on Ultra Low-Dose Estradiol Therapy in Osteoporosis Prevention Marie Foegh,
The FRAX tool for Osteoporosis Should all GP’s be calculating the Frax score prior to treatment Dr Sanjeev Patel Consultant Physician & Senior Lecturer.

The FRAX tool for Osteoporosis Should all GP’s be calculating the Frax score prior to treatment Dr Sanjeev Patel Consultant Physician & Senior Lecturer.
Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist.

Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist.
WHO Osteoporosis Definition (1996)

WHO Osteoporosis Definition (1996)
Downloaded from www.fosamax.aewww.fosamax.ae 1 Alendronate vs. Risedronate Comparison Trial.

Downloaded from 1 Alendronate vs. Risedronate Comparison Trial.
Slide 1 Update on Alendronate and Raloxifene in Osteoporosis EFficacy of FOSALAN ™ vs. Evista ® Comparison Trial (EFFECT) FOSALAN (alendronate) is a trademark.

Slide 1 Update on Alendronate and Raloxifene in Osteoporosis EFficacy of FOSALAN ™ vs. Evista ® Comparison Trial (EFFECT) FOSALAN (alendronate) is a trademark.
Protelos Long-Term Antifracture Efficacy. Protelos Vertebral Antifracture Efficacy over 4 years in SOTI Favors Protelos  RR P

Protelos Long-Term Antifracture Efficacy. Protelos Vertebral Antifracture Efficacy over 4 years in SOTI Favors Protelos  RR P
Osteoporosis Lucy Cowdrey 4 th November 2009. What is it?

Osteoporosis Lucy Cowdrey 4 th November What is it?
Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy The Women’s Health Initiative Randomized Controlled Trial JAMA 2004;291:1701-1712.

Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy The Women’s Health Initiative Randomized Controlled Trial JAMA 2004;291:
Www.osteoporosis.ca 2005 OSC Recommendations for Bone Mineral Density Reporting Slides prepared by Kerry Siminoski, MD, FRCPC William Leslie, M.Sc., MD,

OSC Recommendations for Bone Mineral Density Reporting Slides prepared by Kerry Siminoski, MD, FRCPC William Leslie, M.Sc., MD,
Relationship of Drug Associated Change in Bone Mineral Density to Fracture Risk Marc C. Hochberg, MD, MPH FDA Endocrinologic and Metabolic Drugs Advisory.

Relationship of Drug Associated Change in Bone Mineral Density to Fracture Risk Marc C. Hochberg, MD, MPH FDA Endocrinologic and Metabolic Drugs Advisory.
Osteoporosis Osteoporosis is defined as a loss of bone mass or bone mineral density characterized by height reduction, fractures, back/neck pain, and stooped.

Osteoporosis Osteoporosis is defined as a loss of bone mass or bone mineral density characterized by height reduction, fractures, back/neck pain, and stooped.
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.

Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
Baseline Serum Estradiol and Fracture Reduction during Treatment with Hormone Therapy: The Women's Health Initiative Randomized Trial Jane A. Cauley, DrPH.

Baseline Serum Estradiol and Fracture Reduction during Treatment with Hormone Therapy: The Women's Health Initiative Randomized Trial Jane A. Cauley, DrPH.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Postmenopausal Osteoporosis Overview Bruce Ettinger, MD Senior Investigator Division of Research Kaiser Permanente Medical Care Program Oakland, California.

Postmenopausal Osteoporosis Overview Bruce Ettinger, MD Senior Investigator Division of Research Kaiser Permanente Medical Care Program Oakland, California.
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,

1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
Hormonal Replacement Therapy for postmenopausal females: To give or not to give? Amna B. Buttar, MD, MS Assistant Professor of Clinical Medicine Indiana.

Hormonal Replacement Therapy for postmenopausal females: To give or not to give? Amna B. Buttar, MD, MS Assistant Professor of Clinical Medicine Indiana.
Identification of individuals at high- risk of fracture Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.

Identification of individuals at high- risk of fracture Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.

Similar presentations

Ads by Google